Navigation Links
Patrick J. Sullivan Elected to Gen-Probe Board of Directors

SAN DIEGO, Sept. 20 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that Patrick Sullivan, former chairman, president and chief executive officer of Cytyc Corporation, has been elected to its board of directors.  Gen-Probe's board now has 10 members, including eight independent directors.

"We are delighted that Pat has agreed to join Gen-Probe's already strong board," said Hank Nordhoff, the Company's chairman.  "We expect to benefit greatly from his experiences leading a multi-billion-dollar growth company, and from his deep knowledge of diagnostics and women's health."

Mr. Sullivan, 58, joined Cytyc in 1991 as vice president, sales and marketing.  He became president, CEO and a director in 1994, and added the chairman's title in 2002.  He remained in those roles until the company's merger with Hologic in 2007.  Mr. Sullivan now leads Constitution Medical Investors, a Boston-based private investment firm in partnership with Warburg Pincus, and is also a director of PerkinElmer.  He graduated with distinction from the U.S. Naval Academy and earned an M.B.A., also with distinction, from Harvard University.

About Gen-ProbeGen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe has approximately 27 years of expertise in nucleic acid testing (NAT), and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening.  Gen-Probe is headquartered in San Diego and employs approximately 1,300 people. For more information, go to

Caution Regarding Forward-Looking StatementsAny statements in this press release about our expectations, beliefs, plans, objectives, assumptions, future events or performance are not historical facts and are forward-looking statements.  These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would.  Forward-looking statements are not guarantees of performance.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied.  Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that Gen-Probe may not be able to retain its key employees and directors.  For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and all subsequent periodic reports.  We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of subsequent events.Contact:Michael Watts

Vice president, investor relations and corporate communications


SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AAIPharma Services Corp. Names Patrick Walsh Chief Executive Officer
2. Patrick J. Zenner Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
3. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
4. Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution
5. Low Installation Rates in Retail Pharmacies Across Europe Increase the Growth Potential of the Pharmacy Automation Systems Market, Finds Frost & Sullivan
6. Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products
7. U.S. Ambulatory Electronic Health Record Market Presents Significant Opportunities and Risks for Vendors, Finds Frost & Sullivan
8. Increasing Potential for RIS-driven PACS Modules in Europe, Finds Frost & Sullivan
9. Frost & Sullivan Recognizes QRxPharma for Innovative Pain Relief Product MoxDuo
10. Rising Burden of Diseases Drives the Pharmaceutical Industry in East Africa, Says Frost & Sullivan
11. Frost & Sullivan: Innovative Products and Technologies Strengthen U.S. Spinal Surgery Market
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the Global Cell Surface Testing Market: ... report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Therapeutic Drug Monitoring (TDM) Market: Supplier ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... As part ... For Empowerment ™ attracts volunteers together who want to combine talents and resources ... key stakeholders in the process. The non-profit launched its first major fundraiser on ...
(Date:11/25/2015)... ... 25, 2015 , ... Finnleo, a leader in the traditional and far-infrared sauna ... and far-infrared saunas. , For traditional saunas, Finnleo is offering 20% ... wood, and Finnleo uses only European Grade A Nordic White Spruce from sustainably grown ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... sauna parts and accessories. , Sauna accessories help improve the bather experience in ... personality. From basic styles for the purist looking for simplicity in design to ...
(Date:11/25/2015)... ... 26, 2015 , ... Ministers, senior government and UN agencies, ... Centres of Excellence, and public R&D institutions, civil societies and other partners gathered ... 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- ...
(Date:11/25/2015)... ... 2015 , ... For the first time, Vitalalert is donating half of its ... The partnership between the two groups began in 2014 with Vitalalert pledging a portion ... International was founded in 1954 and is an international Christian-based health organization whose mission ...
Breaking Medicine News(10 mins):